이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mendus 과거 수익 실적

과거 기준 확인 0/6

Mendus의 수입은 연평균 -11.6%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 11.8%의 비율로 증가했습니다. 매출은 연평균 18.2%의 비율로 증가해 왔습니다.

주요 정보

-11.6%

수익 성장률

22.1%

EPS 성장률

Biotechs 산업 성장	0.7%
매출 성장률	18.2%
자기자본 수익률	-15.9%
순이익	-375.8%
다음 실적 업데이트	23 Aug 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Mendus 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:IMMU 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	28	-107	36	102
31 Dec 23	28	-102	37	93
30 Sep 23	1	-104	41	84
30 Jun 23	1	-116	49	89
31 Mar 23	1	-141	50	88
31 Dec 22	3	-139	49	87
30 Sep 22	2	-128	47	79
30 Jun 22	2	-117	41	72
31 Mar 22	2	-119	41	75
31 Dec 21	0	-133	43	86
30 Sep 21	0	-148	41	83
30 Jun 21	0	-138	34	80
31 Mar 21	0	-119	27	68
31 Dec 20	0	-89	18	48
30 Sep 20	16	3	2	7
30 Jun 20	16	-11	4	19
31 Mar 20	17	-31	9	35
31 Dec 19	17	-48	13	49
30 Sep 19	0	-118	26	91
30 Jun 19	0	-112	27	85
31 Mar 19	0	-98	26	72
31 Dec 18	0	-98	26	71
30 Sep 18	0	-90	25	66
30 Jun 18	0	-89	23	65
31 Mar 18	0	-88	22	66
31 Dec 17	0	-80	23	58
30 Sep 17	0	-86	41	45
30 Jun 17	0	-77	48	28
31 Mar 17	0	-72	58	14
31 Dec 16	0	-61	61	0
30 Sep 16	0	-48	47	0
30 Jun 16	0	-44	43	0
31 Mar 16	0	-37	37	0
31 Dec 15	0	-38	38	0
30 Sep 15	0	-37	38	0
30 Jun 15	0	-36	36	0
31 Mar 15	0	-33	34	0
31 Dec 14	0	-28	28	0
30 Sep 14	0	-21	22	0
30 Jun 14	0	-16	17	0
31 Mar 14	0	-13	14	0
31 Dec 13	0	-10	11	0

양질의 수익: IMMU 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IMMU 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IMMU 은(는) 수익성이 없으며 지난 5년 동안 연간 11.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IMMU 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IMMU 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 3% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IMMU 현재 수익성이 없기 때문에 마이너스 자본 수익률( -15.93% )을 갖습니다.

Mendus 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Recent updates

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Independent Director exercised options to buy kr460k worth of stock.

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

Chief Executive Officer recently bought kr120k worth of stock

We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate

Mendus AB (Publ) Announces Clinical Pipeline Update

Consensus revenue estimates increase by 172%

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Consensus revenue estimates decrease by 63%

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates increase by 172%

Mendus AB (publ), Annual General Meeting, May 17, 2024

New major risk - Share price stability

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Mendus (STO:IMMU) Is Making Moderate Use Of Debt

Price target decreased by 23% to kr5.00

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Is Mendus (STO:IMMU) Using Debt Sensibly?

Price target decreased to kr5.30

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Is Mendus (STO:IMMU) Using Debt Sensibly?

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Chief Financial Officer recently bought kr216k worth of stock

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr97k worth of stock

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Is Immunicum (STO:IMMU) Using Too Much Debt?

Chief Executive Officer recently bought kr252k worth of stock

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought kr2.4m worth of stock

Interim Chairman of the Board recently bought kr183k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Executive Officer has left the company

Immunicum Announces Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer

Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors

New 90-day low: kr6.84

Independent Chairman Michael S. Oredsson has left the company

Immunicum AB (Publ) Announces Executive Changes